Loading
Exelixis, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by JOHNSON DAVID EDWARD, was filed 26 Nov 2025.
Insider Decl.
1,332
Thresholds
n/a
Buy Volume
€13M
6 ops. · all time
Sell Volume
€308M
436 ops. · all time
Who traded when
BuySalePatrick J. Haley16 sales
Dana Aftab7 sales
Julie Smith5 sales
Mary C. Beckerle5 sales
Sue Gail Eckhardt5 sales
Christopher J. Senner4 sales
+10 other insiders
Since the insiders bought
- +46.2%Entry US$44.17 · Close 21 Oct 2026 US$64.58
- +316.4%Entry US$5.19 · Close at T+365 US$21.61
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Exelixis, Inc. Buy (bullish), based on 15 analysts. Average price target: US$55.53.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 2,920 of 26,240 companies
73.1
score / 100
Value52
Quality94
FCF yld5.3%
Earn yld4.9%
EV/EBITDA17.5x
ROE44%
Gross mgn96%
Net mgn34%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$64.58
Analyst consensus
15 analystsBuy
US$41.00Target US$55.53(-14%)US$70.00
Income statement
RevenueUS$2.3B
Gross profitUS$2.2B96% margin
EBITDAUS$921.8M40% margin
Net incomeUS$782.6M35.3% margin
Valuation
PER (trailing)20.4x
PER (forward)15.1x
P/Book8.7x
Beta0.47
Balance sheet & cash
Market capUS$16B
Total debtUS$173M
Free Cash FlowUS$844.3M
Debt / Equity9%
Profitability & ownership
ROE44.4%
ROA24.0%
% insiders1.8%
% institutions107.0%
Last declaration on 12 August 2026
Declarations1,332 total
9,812 shares@ US$53.660.0037% mcap60.1% of flowCommon StockSEC:0000939767-26-000101:0
9,812 shares@ US$53.65840.0037% mcap100.0% of flowCommonSEC144:0001950047-26-007854
8,367 shares0Common StockSEC:0000939767-26-000078:0
8,367 shares0Common StockSEC:0000939767-26-000075:0
8,367 shares0Common StockSEC:0000939767-26-000076:0
8,367 shares0Common StockSEC:0000939767-26-000077:0
8,367 shares0Common StockSEC:0000939767-26-000079:0
8,367 shares0Common StockSEC:0000939767-26-000080:0
8,367 shares0Common StockSEC:0000939767-26-000081:0
8,367 shares0Common StockSEC:0000939767-26-000082:0
8,367 shares0Common StockSEC:0000939767-26-000083:0
43,451 shares@ US$50.350.015% mcap10.8% of flowCommon StockSEC:0000939767-26-000070:0
32,110 shares@ US$49.810.011% mcap9.8% of flowCommon StockSEC:0000939767-26-000069:0
30,578 shares@ US$51.100.010% mcap7.7% of flowCommon StockSEC:0000939767-26-000064:0
60,000 shares@ US$45.710.020% mcap38.5% of flowCommon StockSEC:0000939767-26-000061:0
160,437 shares0Common StockSEC:0000939767-26-000033:1
23,119 shares0Common StockSEC:0000939767-26-000035:0
40,459 shares0Common StockSEC:0000939767-26-000034:0
100,278 shares0Common StockSEC:0000939767-26-000033:0
52,018 shares0Common StockSEC:0000939767-26-000037:0
52,018 shares0Common StockSEC:0000939767-26-000036:0
47,918 shares@ US$44.5010.4% of flowCommon StockSEC:0000939767-26-000032:0
29,873 shares@ US$44.356.5% of flowCommon StockSEC:0000939767-26-000031:0
99,574 shares@ US$44.0142.0% of flowCommon StockSEC:0000939767-26-000030:1
20,634 shares@ US$19.770.0030% mcap20.6% of flowCommon StockSEC:0000939767-26-000030:0
25 of 1332 declarations
About Exelixis, Inc.
At Exelixis, Inc., purchases are rare but large: 6 purchases worth EUR 12,983,656, with a median of EUR 2,333,786, or 1% of open-market trades, against 436 sales worth EUR 308,339,290 (median EUR 502,556). The three largest purchases are all David Edward Johnson's (Director): EUR 4,309,994 on May 30, 2024, EUR 3,744,884 on May 28, 2024 and EUR 3,636,992 on February 21, 2024.
The three largest sales are Patrick J. Haley's (EVP, Commercial), EUR 4,996,298 on May 15, 2025, Christopher J. Senner's (EVP and CFO), EUR 4,109,824 on May 16, 2025, and Stelios Papadopoulos's (Director), EUR 3,758,365 on November 12, 2025.
Read moreShow less
The 1,332 filings from 28 insiders were published from January 5, 2016 to August 12, 2026, with 463 grants, 348 option exercises and 79 filings of another kind. 2020 is the busiest year (234), ahead of 2019 (198) and 2021 (162); 2022 has only 75. Michael Morrissey (President and CEO) files the most, 274, of which 59 sales, ahead of Patrick J. Haley (166) and Jeffrey Hessekiel (132). Over the last twelve months: 77 filings, 1 purchase, 26 sales. The median delay is 2 days.
This US healthcare and pharma company is worth USD 15.5 billion; insiders hold 1.8% of the capital.
